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Abstract 17 
Wolbachia, a common vertically transmitted symbiont, can protect insects against viral infection and 18 
prevent mosquitoes from transmitting viral pathogens. For this reason, Wolbachia-infected 19 
mosquitoes are being released to prevent the transmission of dengue and other arboviruses. An 20 
important question for the long-term success of these programs is whether viruses can evolve to 21 
escape the antiviral effects of Wolbachia. We have found that Wolbachia altered the outcome of 22 
competition between strains of the DCV virus in Drosophila. However, Wolbachia still effectively 23 
blocked the virus genotypes that were favoured in the presence of the symbiont. We conclude that 24 
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Wolbachia did cause an evolutionary response in viruses but this has little or no impact on the 25 
effectiveness of virus-blocking. 26 
 27 
Introduction 28 
Wolbachia is a maternally-transmitted intracellular bacterium found in many insects (1). Its ability to 29 
rapidly spread through insect populations by inducing a sperm-egg incompatibility called cytoplasmic 30 
incompatibility (2–4) coupled with its inhibitory effect on the replication of RNA viruses (5–8) make it 31 
a promising control agent to prevent the transmission of mosquito-borne diseases (9). In several 32 
parts of the world the bacterial symbiont is being introduced into natural populations of the 33 
mosquito Aedes aegypti, the main vector of dengue and Zika viruses (10–13). Preliminary field 34 
releases of Wolbachia-infected Ae. aegypti females have demonstrated that the bacterial infection is 35 
able to spread and be stably maintained (4,10,11), turning susceptible populations of mosquitoes 36 
into virus-resistant ones (14). 37 
Like other control methods, there is a risk that the release of Wolbachia-infected mosquitoes may 38 
not be evolution-proof.  It may promote adaptive changes in the mosquito vector, Wolbachia or 39 
virus that could hamper the long-term success of field interventions. Therefore, there is an urgent 40 
need to understand and predict what genetic changes might follow the introduction of Wolbachia, 41 
especially because such introductions are likely to be irreversible (15,16). For instance, high antiviral 42 
resistance is associated with high densities of the symbiont within the insect tissues (17,18), and this 43 
leads to reductions in the fecundity, lifespan and other fitness-related traits of the insect host 44 
(11,19–22). These costs may lead to the evolution of lower Wolbachia densities and thus a reduction 45 
or loss of the antiviral phenotype. A second concern is the evolution of the virus itself. Since 46 
Wolbachia blocks the transmission of the virus by inhibiting its replication, virus populations should 47 
be selected to overcome such inhibition. Potentially, virus strains that are able to replicate at a 48 
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higher rate in the presence of Wolbachia could be advantaged and spread. For example, the 49 
intensity of Wolbachia’s effect on dengue transmission varies between virus serotypes (14), and the 50 
magnitude of these differences is sufficiently large that it is predicted to alter the outcome of control 51 
programs (23). Therefore, if viruses can escape the resistance conferred by Wolbachia, this would 52 
threaten the sustainability of symbiont-based interventions.  53 
Here we passaged Drosophila C virus (DCV) through Wolbachia-infected Drosophila melanogaster 54 
and examined how the symbiont affected the evolution of the virus. DCV is a positive-strand RNA 55 
virus of the family Discistroviridae that naturally infects D. melanogaster (24). It is highly pathogenic 56 
in laboratory experiments, leading to fly death within a few days(25). Wolbachia leads to large 57 
reductions in DCV titres and increases survival after DCV infection, which has led to DCV becoming a 58 
common model to study Wolbachia-mediated antiviral protection (5,17,18). We found that 59 
populations of the virus became genetically differentiated from controls in Wolbachia-free flies, with 60 
the same viral genotype being favoured across replicate populations. However, despite these 61 
parallel genetic changes providing evidence of adaptive evolution in the viral populations, we could 62 
not detect any reduction in Wolbachia’s antiviral effect or any increase in DCV virulence. 63 
 64 
Methods 65 
 66 
Fly husbandry and virus isolates 67 
D. melanogaster lines previously described in (21) were kindly provided by Luis Teixeira. The DrosDel 68 
w1118 isogenic background was used as the Wolbachia-free control. The Wolbachia-infected line was 69 
created in (21) by introgressing the DrosDel w1118 nuclear background into a cytoplasm infected with 70 
the Wolbachia strain wMelCS_b through chromosome replacement using balancers for the first, 71 
second and third chromosomes (the fourth chromosome was not replaced). Flies were maintained 72 
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on a cornmeal diet (1200ml water,13g agar,105g dextrose,105g maize,23g yeast,35ml Nipagin) at 73 
25°C under a 12h light-dark cycle and 70% humidity. 74 
DCV isolates were previously described in (26) and kindly provided by Karyn N. Johnson. Isolates 75 
DCV-C and -G originate from France, DCV-EB and -CYG from Australia and DCV-M, -O, -T and -Z from 76 
Morocco. 77 
 78 
Virus production 79 
All DCV isolates were passaged once in Schneider Drosophila Line cells (DL2) before the series of 80 
experiments. Cells were cultured at 26.5°C in Schneider’s Drosophila medium with 10% foetal bovine 81 
serum, 100 U/ml penicillin and 100 mg/ml streptomycin (all Invitrogen, UK). Cells were then freeze-82 
thawed twice to lyse cells and centrifuged at 4,000 g for 10 min at 4°C to remove cellular debris. 83 
Finally, the supernatant containing DCV was aliquoted and frozen at -80°C.  84 
For infection assays, aliquots of virus solutions were defrosted on the day of infection. Virus aliquots 85 
were diluted in Ringer’s solution (27) to standardise the concentration of DCV RNA measured by 86 
quantitative PCR (qPCR, see section on DCV titer below for primers and amplification cycles). The 87 
concentration of DCV RNA was used instead of the TCID50 method (28) as the cytopathic effects of 88 
the eight DCV isolates differed considerably. Total RNA from the eight virus solutions was extracted 89 
and a standard Wolbachia spike-in added during the RNA extraction. The DCV critical threshold 90 
values were then normalized relative to the Wolbachia gene atpD using primers atpDQALL_F (5'-91 
CCTTATCTTAAAGGAGGAAA-3') and atpDQALL_R (5'-AATCCTTTATGAGCTTTTGC-3').  92 
 93 
 94 
 95 
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Sequencing of DCV genome and phylogenetic analysis 96 
Viral RNA was extracted using TRIzol reagent (Invitrogen) and reverse-transcribed with the Maxima 97 
H Minus Reverse Transcriptase (ThermoFisher Scientific) and oligo dT primers. The DCV genome was 98 
then amplified by PCR using a set of 22 primers distributed along the 9,264 bp genome (Table S1). 99 
For each genome, the eleven PCR products were Sanger-sequenced and the reads assembled into a 100 
consensus genomic sequence using the Sequencher v4.5 software (GenBank accession numbers: 101 
MK645238-MK645245). DCV genomes were aligned with ClustalW in BioEdit v7.0.9 (29). A maximum 102 
likelihood phylogenetic tree was built using the aligned genomes and node supports were assessed 103 
with 1,000 bootstrap replications. 104 
 105 
Selection experiment 1 on genetically diverse virus populations 106 
To investigate virus adaptation from standing genetic variation, we created a virus population 107 
composed of equal proportions of each of the eight DCV isolates based on the relative amount of 108 
DCV RNA in the original virus solutions. The DCV mixture was then passaged in flies with or without 109 
Wolbachia by infecting 3-6 day old female flies (Passage 1). For this, flies were anaesthetized on CO2 110 
and stabbed on one side of the thorax with a steel needle (Austerlitz Insect Pins) dipped into the 111 
virus solution as explained in (30). Ten flies were then transferred to a vial containing cornmeal food. 112 
Twelve vials per Wolbachia treatment were prepared, representing twelve biological replicates. 113 
Virus populations were harvested three days post-infection by homogenizing the ten virus-infected 114 
flies from each vial in 25 µl of Ringer solution. The homogenate was then centrifuged at 12,000g and 115 
10 µl of the supernatant was frozen at -80°C and later used as the inoculum for further passage. The 116 
remaining 20 µl containing the fly tissues were diluted in 250 µl of TRIzol reagent and frozen at -80°C 117 
for later RNA extraction. The virus populations were serially passaged two more times (Passages 2 118 
and 3) by repeating the steps above and infecting new flies from the respective Wolbachia 119 
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treatment. Note the amount of virus in the inoculum was only controlled at the start of selection 120 
(Passage 1). In order to avoid cross-contamination between virus populations, different tools 121 
(needles, handling brushes) were used for each replicate population at each passage. 122 
 123 
Pool-Sequencing, read processing, mapping and variant identification  124 
Total RNA was extracted from flies in Passage 3 of the selection experiment 1. Since the DCV 125 
genome contains a poly(A) tail, we isolated the virus genomic RNA along with fly transcripts by 126 
capturing the polyadenylated RNAs from the extracted total RNA using the KAPA Stranded mRNA-127 
Seq kit (Kapa Biosystems) and a different indexed adapter for each RNA library. Twenty-four libraries 128 
were prepared (one per virus population), quantified by qPCR and pooled in equal proportions into a 129 
multiplexed library. The pool was sequenced in one lane of Illumina HiSeq4000 to generate single-130 
end 50bp reads (SRA study accession number PRJEB21984). 131 
We used Trimmomatic v0.32 (31) to trim reads. We first removed three bases from 3’ end of the 132 
read. Reads were quality trimmed from the 3′ end, cutting when average quality scores in sliding 133 
windows of 4 bases dropped below 15. We required reads have a minimum length of 36. Using BWA 134 
MEM (32), we mapped reads to the genome of a genetically homogenous DCV population (DCV-ref) 135 
previously produced from the isolate DCV-C by endpoint dilution (33).  We removed optical 136 
duplicate reads using Picard tools (https://broadinstitute.github.io/picard/). We realigned reads 137 
close to indels using GATK (34). Following that, we used Samtools (35) to remove reads with 138 
mapping quality scores lower than 40. We also used Samtools to generate a multi-pileup file to assist 139 
with variant identification.  Finally, we used PoPoolation2 to identify the allele frequency of the 140 
variants in the pooled genomic library samples (36). To make the statistical power and influence of 141 
different variants and libraries similar, we down-sampled sites to a maximum coverage of 142 
50x/library. 143 
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 144 
Recombination analysis 145 
In order to investigate the extent of recombination of the DCV genome in selection experiment 1, we 146 
resequenced the 24 RNA libraries using MiSeq to generate paired-end 250 bp reads (SRA study 147 
accession number PRJEB21984). The software bcl2fastq on BaseSpace (Illumina Inc, San Diego) was 148 
used to demultiplex the base call files to Fastq files, trim adaptor sequences using a sliding window 149 
with an adapter stringency of 0.9. We then used Trimmomatic (31) to cut reads at the first base 150 
where the quality score (Q) dropped below 30, retaining only reads with a minimum length of 35 bp. 151 
These were mapped to the genome of isolate DCV-C (Genbank accession number MK645242) using 152 
BWA MEM (32). We used Picard tools (https://broadinstitute.github.io/picard/) to reorder reads, 153 
add read groups and sort them by coordinates. Mapped reads were converted into a table of 154 
variants where each row is a separate sequence read using sam2tsv in JVarkit (37). The reads from 155 
all libraries were combined. We kept properly paired reads, as identified by their SAM flags, with at 156 
least one SNP of interest in each of the forward and reverse reads using custom scripts that are 157 
deposited in the Dryad Data Repository 158 
(https://datadryad.org/review?doi=doi:10.5061/dryad.18j31ch). When a site had the DCV-C allele, 159 
we then counted the proportion of read-pairs where the other SNP either had the DCV-C allele (non-160 
recombinant) or the alternate allele (recombinant). As polymorphisms segregating in the founding 161 
viral populations can give a spurious signal of recombination in this analysis (38), we removed any 162 
pairs of SNPs where the ratio of reads carrying the two possible products of recombination deviated 163 
from the expected 50:50 ratio (binomial test, p < 0.01). We tested whether the fraction of 164 
recombinant reads between pairs of SNPs increased with distance between the SNPs using logistic 165 
regression, accounting for over dispersion using a quasibinomial model. Retaining only pairs of SNPs 166 
that were represented by at least 25 read pairs, we regressed the proportion of recombinant reads 167 
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against the distance between the SNPs to estimate the fraction of recombinants between adjacent 168 
nucleotides.  169 
 170 
DCV titer 171 
Total RNA was extracted three days post-infection from pools of ten DCV-infected flies. Five 172 
biological replicates (10 flies each) were performed per Wolbachia treatment, DCV isolate (single 173 
infection experiment) or DCV population (selection experiments). The extracted RNA was reverse-174 
transcribed with Promega GoScript reverse transcriptase (Promega) and random hexamers. The 175 
amount of virus RNA was quantified with qPCR by amplifying a 135 bp region of the DCV genome 176 
with primers DCV_S (5’-GACACTGCCTTTGATTAG-3’) and DCV_AS (5’-CCCTCTGGGAACTAAATG-3’) 177 
targeting regions that are conserved among the DCV isolates used in this study. Additionally, we 178 
quantified the fly gene actin 5C in a separate reaction (forward: 5’-179 
GACGAAGAAGTTGCTGCTCTGGTTG-3’ ; reverse: 5’-TGAGGATACCACGCTTGCTCTGC-3’ ; 193 bp 180 
product). The qPCR cycle was 95°C for 2 min, followed by 40 cycles of 95°C for 5 s and 60°Cfor 30 s. 181 
Two reactions per sample and per target gene were performed and the mean Ct value of the two 182 
technical replicates was used to calculate the relative amount of DCV RNA per fly as 2∆Ct, with ∆Ct = 183 
Ctfly gene – CtDCV.  184 
 185 
Virus-induced mortality 186 
Flies were infected with each DCV isolate or with Ringer’s solution (mock-infected controls) as above 187 
except that biological replicates consisted of vials with 20 females. Following infection, flies were 188 
transferred onto fresh food every three days and survival was recorded daily for 15 days post-189 
infection. 190 
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 191 
Selection experiment 2 on genetically homogenous virus populations 192 
In order to study virus evolution from de novo mutation, we used a similar protocol as in the 193 
selection experiment on genetically diverse virus populations. We passaged the homogenous DCV 194 
population DCV-ref (33) for ten passages in either Wolbachia-free or Wolbachia-infected flies (25 195 
replicate populations in each treatment). The only difference was that male flies were used instead 196 
of females and viruses were harvested two days post-infection instead of three. Flies were initially 197 
infected in passage 1 with a virus concentration of 6.32 × 108 TCID50/mL.  198 
 199 
Statistical analysis 200 
All statistical analysis were done in the R software v3.2.3 (39) and R scripts deposited in the Dryad 201 
Data Repository (https://datadryad.org/review?doi=doi:10.5061/dryad.18j31ch). Pairwise genetic 202 
distances between virus populations of the selection experiment 1 were calculated as the probability 203 
of drawing different alleles from two different populations Pdiff = 1 - (ppop1 × ppop2 + qpop1 × qpop2) 204 
where ppop1 and ppop2 are the mean frequencies of reference alleles in population 1 and 2 and qpop1 205 
and qpop2 the mean frequencies of the alternative allele. We conducted a Mantel test with 1,000 206 
permutations by randomly attributing Wolbachia treatments to populations. The p-value was 207 
obtained by comparing the observed mean genetic distance between treatments with the null 208 
distribution of mean genetic distances obtained by permutation. 209 
The principal component analysis was performed with the function dudi.pca (R package ade4). For 210 
each Wolbachia treatment, 95% confidence ellipses were computed with the assumption of 211 
multivariate normal distribution of the data using the function stat_ellipse (R package ggplot2). The 212 
discriminant analysis of principal components was performed with the function dapc (R package 213 
adegenet (40)). 214 
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Viral titers were analyzed with a linear model after log10 transformation of the data to meet the 215 
assumptions of normality and homoscedasticity. For the experiment measuring viral titers of evolved 216 
populations, the virus population was treated as a random effect in a linear mixed effect model 217 
(package LmerTest). For the time-course analysis of DCV titer, 3 parameter asymptotic exponential 218 
growth curves were fitted to the log2 viral titer using the function nls (R package stats). To test 219 
whether there was an effect of Wolbachia on the growth curve, we used a likelihood ratio test to 220 
compare the fit of a single curve to all the data with the fit of separate curves to the data from 221 
Wolbachia-infected and Wolbachia-free flies.  To test whether there were either differences in the 222 
growth of the three viruses or there were virus-specific effects of Wolbachia, we compared our two-223 
curve model (Wolbachia + and -) to a six-curve model (a separate curve for each of the three viruses, 224 
with and without Wolbachia).  When plotting the curves, 95% confidence intervals were estimated 225 
by Monte Carlo simulation.  226 
Fly survival was analyzed with a Cox’s proportional hazard mixed-effect model (R package coxme). 227 
Flies that were alive at the end of the experiment were treated as censored data. Multiple pairwise 228 
comparisons were performed with the function glht (R package multcomp, (41)). 229 
 230 
Results 231 
 232 
Virus populations evolve in response to Wolbachia  233 
In order to test whether DCV adapts to the presence of Wolbachia, we passaged a genetically 234 
diverse population of viruses through Wolbachia-infected or Wolbachia-free flies (selection 235 
experiment 1). The viral population was founded by mixing eight DCV isolates collected from both 236 
laboratory stocks and wild D. melanogaster from around the world (26). The mixture initially 237 
contained equal concentrations of viral RNA from each DCV isolate and after three passages, we 238 
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sequenced the polyadenylated RNA from twelve independent replicates per Wolbachia treatment. 239 
The mean depth of coverage of each replicate ranged from 65 to 89x (Table S2). After filtering out 240 
variants with a mean minor allele frequency below 5% there were 167 Single Nucleotide 241 
Polymorphisms (SNPs). Among these, 161 were found among the genomes of the eight DCV isolates 242 
used to found the viral population. There were 703 SNPs among the founding DCV genomes, 243 
suggesting that ~77% had minor allele frequencies below 5% by the end of the selection experiment. 244 
Parallel evolution, where the same genetic changes evolve independently in response to the same 245 
selection pressure, provides evidence of adaptation. To test for parallel evolution in our experiment 246 
we calculated the genetic distance between all possible pairs of populations. We found that the 247 
mean genetic distance between DCV populations from the same Wolbachia treatment (Wolbachia-248 
infected or Wolbachia-free flies) was less than between populations from different Wolbachia 249 
treatments (Mantel test, P = 0.028, Figure S1A). Parallel evolution of the DCV populations was also 250 
apparent in a Principal Component Analysis (PCA) on DCV allele frequencies, where the second 251 
principle component separated DCV populations depending on whether or not they had evolved in 252 
flies infected with Wolbachia (Figure 1A).  253 
 254 
Wolbachia alters the frequency of viral genotypes in the population 255 
The evolutionary response to Wolbachia could either involve changes in the frequency of the eight 256 
founding viral genotypes or selective sweeps of specific SNPs through a recombining population of 257 
viruses. We calculated the difference in the frequency of SNPs between the populations that had 258 
evolved in flies with and without Wolbachia (Figure 1B). Across the viral genome, alleles from the 259 
DCV-C isolate consistently showed higher frequencies in the presence of Wolbachia (Figure 1B), 260 
while the DCV-EB, -CYG and -G alleles had lower frequencies. All of the variants that were at a 261 
substantially higher frequency in the Wolbachia-infected flies were present in DCV-C, and these 262 
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were scattered across the genome (Figure 1B). Alleles specific to the DCV-C isolate have increased in 263 
frequency in both the Wolbachia-infected and Wolbachia-free flies, reaching mean frequencies of 264 
77% and 67% respectively (based on DCV-C specific alleles, Figure S1). Therefore, DCV-C was 265 
successful in all the populations, but its competitive advantage has been increased with Wolbachia. 266 
These analyses suggest that there may have been limited recombination in the population, and the 267 
frequency of the founding viruses has changed in response to selection by Wolbachia. To confirm 268 
this we generated longer sequence reads from the same samples and used read-pairs containing 269 
multiple SNPs to examine the rate at which DCV-C had recombined with other viral isolates. We 270 
found that there were more putative recombination events between SNPs that were further apart in 271 
the genome, as expected if there is recombination (logistic regression: t = 4.45, p = 0.0001). By 272 
estimating a per bp recombination rate and extrapolating this to the whole genome, we estimate 273 
that 86% of DCV-C genomes will have survived intact without recombination by the end of the 274 
experiment. This supports the conclusion that we are primarily looking at changes in the frequency 275 
of the founding viruses. 276 
As there is limited recombination between DCV isolates, we can use SNPs as markers to track 277 
changes in the frequency of different viral isolates. We first reconstructed the phylogeny of the DCV 278 
isolates using their Sanger-sequenced genomes (Figure 1C), finding similar relationships to published 279 
analyses of restriction fragment length polymorphisms (26). In the evolved populations, we 280 
identified isolate-specific alleles for four isolates (Figure 1D; DCV-C, -E, -M and -T), while DCV-G and 281 
DCV-O are polymorphic since their genomes contain high numbers of ambiguous bases (Table S3). 282 
Larger numbers of SNPs were found that defined clades of viruses on the phylogeny (Figure 1C and 283 
D). Comparing the frequency of these SNPs among our evolved populations confirmed that DCV-C 284 
was favoured in Wolbachia-infected flies, while alleles specific to the clade containing DCV-EB, -CYG 285 
and -G decreased in frequency by around 10% in the presence of Wolbachia. There was little 286 
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difference between Wolbachia treatments in the frequency of isolates in the other clade on the 287 
phylogeny (DCV-M, -Z, -T and -O; Figure 1C and D).   288 
To further examine the genetic basis of differentiation between the DCV populations in Wolbachia-289 
infected and Wolbachia-free flies, we used discriminant analysis on the principal components 290 
(DAPC).  The virus populations showed a bimodal distribution which separates the Wolbachia 291 
treatments (Figure S2A). The genetic differentiation is driven by SNPs across the viral genome, which 292 
is consistent with there being limited recombination (Figure S2B). Alleles specific to the isolate DCV-293 
C and the EB-CYG-G clade consistently contributed the most to the genetic differentiation between 294 
Wolbachia treatments (Figure S2C). This confirms that DCV-C was favoured in the presence of 295 
Wolbachia and that this was at the expense of viruses in the EB-CYG-G clade.  296 
 297 
The DCV isolate favoured in Wolbachia-infected flies does not evade the symbiont’s antiviral 298 
effects  299 
Wolbachia may be selecting for viruses that evade its antiviral effects.  In order to investigate this we 300 
inoculated Wolbachia-free and Wolbachia-infected flies with the DCV isolate that increased in 301 
frequency in the presence of Wolbachia (DCV-C), one isolate that decreased in frequency (DCV-EB) 302 
and one isolate which frequency was little affected by Wolbachia (DCV–M). Viral titers were 303 
measured over 6 days to allow an asymptotic exponential growth curve to be fitted to the data. We 304 
found that Wolbachia altered the growth curve of DCV (Figure 2A; χ2=36.8, df=4, p<0.0001), reducing 305 
both the viral growth rate and the final viral titer. However, there was no difference in the growth 306 
curves of the three viral isolates, regardless of whether the flies were infected with Wolbachia 307 
(Figure 2A; χ2=20.6, df=16, p=0.20). Therefore, we found no evidence that Wolbachia has favoured 308 
viral isolates that overcome the symbiont’s antiviral properties. 309 
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We also measured the ability of the DCV isolates to kill Wolbachia-free and Wolbachia-infected flies. 310 
Levels of mortality varied among virus isolates, with flies infected with DCV-CYG showing the lowest 311 
mortality, regardless of whether the flies carried Wolbachia (Figure 2B ; Main effect virus: χi2 = 312 
125.29, d.f. = 10, P < 0.0001). Wolbachia had no effect on the survival of mock-infected flies (control 313 
in Figure 2B), but in all cases increased survival of DCV-infected flies (Figure 2B and C ; Main effect 314 
Wolbachia: χi2 = 132.7, d.f. = 6, P < 0.0001). The magnitude of the protective effects of Wolbachia 315 
depended on the DCV isolate (Figure 2B and C ; Wolbachia-by-Virus interaction: χi2 = 16.7, d.f. = 2, P 316 
= 0.005). However, there was no association between the extent to which Wolbachia protected flies 317 
against the virus (Figure 2B) and whether that virus increased in frequency in the presence of 318 
Wolbachia (Figure 1).  319 
 320 
Virus populations evolved with Wolbachia did not adapt to counteract its antiviral effect 321 
To test whether virus had adapted to overcome the antiviral effects of Wolbachia, we randomly 322 
chose five virus populations from each of the selection treatment and infected flies with equal 323 
concentrations of viral RNA (see methods). The viral titer three days post-infection was lower in 324 
Wolbachia-infected flies, regardless of the selection regime (Wolbachia effect: χi2 = 158.68; P < 325 
0.0001; Figure S3 for pairwise comparisons). Surprisingly, the effect of Wolbachia on viral titers was 326 
slightly greater for the viral populations that had been passaged through Wolbachia-infected flies 327 
(Wolbachia-by-selection effect: χi2 = 4.34; P = 0.04; Figure S3). Therefore, viruses evolved with the 328 
symbiont were still susceptible to the inhibitory effect of Wolbachia.  329 
 330 
 331 
  332 
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A genetically homogenous virus population did not evolve to escape the antiviral effects of 333 
Wolbachia 334 
The high mutation rates, replication rates and population sizes of many viruses mean that they can 335 
frequently evolve to overcome host resistance during selection experiments through de novo 336 
mutations. To test whether this was the case for Wolbachia and DCV, we serially passaged a 337 
genetically homogenous population of the DCV-C isolate through Wolbachia-free and Wolbachia-338 
infected flies (selection experiment 2). While DCV was maintained at high titers in Wolbachia-free 339 
flies, titers tended to progressively decrease in the presence of the symbiont and frequently became 340 
undetectable (Figure 3A). After ten passages, only two of 25 replicates in Wolbachia-infected flies 341 
had DCV titers close to those observed in the absence of the symbiont (Figure 3A). We tested 342 
whether these two virus populations had maintained high titres by evolving to counter the antiviral 343 
effects of Wolbachia by infecting new flies with equal concentration of viral RNA. There was no 344 
significant difference in the effects of Wolbachia on these viruses compared to control populations 345 
passaged through Wolbachia-free flies (Figure 3B ; Wolbachia effect: F1,44 = 113.95 ; P < 0.0001 ; 346 
Selection effect:  F1,44 = 0.72 ; P = 0.4 ; Wolbachia-by-selection interaction: F1,44 = 3.25 ; P = 0.08). 347 
 348 
Discussion 349 
Wolbachia is able to block the replication of RNA viruses and this is being harnessed by public health 350 
programmes to control mosquito-borne diseases (42). The impact of such interventions on evolution 351 
of the viruses is unknown. If viruses could evolve to escape Wolbachia’s antiviral effects, or 352 
Wolbachia selects for increased viral virulence in the mosquito or human host, this would have 353 
important implications for control programs. For example, interventions that reduce the growth rate 354 
of a pathogen without clearing the infection can select for compensatory increases in replication 355 
rates that in turn increase virulence (43). We found that Wolbachia can alter the evolution of a 356 
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virus—when DCV evolved in the presence of Wolbachia there were replicable genetic changes in 357 
viral population. This was mediated by Wolbachia modifying competition between virus strains 358 
within the insect. However, these changes neither allow the virus to escape Wolbachia’s blocking 359 
effect nor alter the virus’s virulence. 360 
In our first experiment, we passaged a genetically diverse viral population through Wolbachia-361 
infected flies in an attempt to select for viruses that escaped the symbiont’s antiviral effects. At the 362 
genetic level there was a clear response to selection, with the DCV-C genotype reaching higher 363 
frequencies in the presence of Wolbachia. However, we were unable to find any evidence that DCV-364 
C either had higher virulence or escaped Wolbachia’s antiviral effects.  It is possible DCV-C was 365 
favoured because of Wolbachia altering the strength of competition between viruses. While the 366 
mechanisms of the Wolbachia-mediated antiviral effect remain elusive, previous studies have shown 367 
that competition between the symbiont and viruses for resources such as cholesterol might be 368 
involved (44,45). By reducing the availability of these resources, Wolbachia might exacerbate fitness 369 
differences that already exist between virus isolates. Consistent with this, DCV-C increased in 370 
frequency in Wolbachia-free flies, but to a lesser extent than in the presence of Wolbachia. 371 
In the second selection experiment we tested virus adaptation from de novo mutation. Selection 372 
was strong, leading to the loss of most viral populations across serial passages. The few virus 373 
populations that managed to persist in the presence of the symbiont still suffered large reductions in 374 
titer in Wolbachia-infected flies. Therefore, we were unable to select for major-effect Wolbachia-375 
escape mutations in the virus, and it is possible these viruses simply persisted due to stochastic 376 
processes. This is similar to a recent study where dengue virus populations evolved in Wolbachia-377 
infected mosquito cell lines showed rapid decline and frequently went extinct (46). Strikingly, the 378 
few dengue-infections that persisted in the presence of Wolbachia showed an almost complete 379 
inability to replicate in both Wolbachia-free and Wolbachia-infected cells following selection. We did 380 
not observe this with DCV, but our mixed DCV populations evolved with Wolbachia showed slightly 381 
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lower replication in Wolbachia-infected flies (Figure S3), i.e. they appeared to be more affected by 382 
Wolbachia than populations evolved without symbiont. It is possible that the presence of Wolbachia 383 
leads to the production of more defective viral genomes (47,48). However the size of this effect was 384 
modest, and whether this is a general pattern remains to be investigated.  385 
The reason why viruses do not readily evolve to escape the antiviral effects of Wolbachia is unclear. 386 
However, clues come from two patterns that are recurrently observed. First, strong antiviral 387 
protection is associated with high symbiont density within cells (17,18,21). Second, Wolbachia 388 
provides protection against a diverse array of distantly related RNA viruses, including viruses whose 389 
natural hosts are Wolbachia-infected (17,49,50). This is reminiscent of ‘quantitative’ plant defenses 390 
against insect herbivores (51). These are secondary metabolites that are produced in large 391 
quantities, and protect against a broad array of herbivores by reducing the digestibility of the plant. 392 
These contrast with ‘qualitative’ toxin defenses that are produced in low quantities (51). While 393 
specialist herbivores frequently evolve to escape qualitative defenses, quantitative defenses are 394 
thought to be more ‘evolution proof’ (51,52). As discussed above, one of the leading hypotheses to 395 
explain the antiviral effects of Wolbachia is that the symbiont competes with the virus for resources 396 
such as cholesterol (44,45). If these resources are essential to viral replication, such a mechanism 397 
may be a form of quantitative defense which viruses cannot readily evolve to escape from. This 398 
contrasts with ‘qualitative’ forms of antiviral protection, such as restriction factors, changes to 399 
surface receptors or drugs, where virus escape may evolve by altering the molecular target of the 400 
antiviral effector. 401 
The final verdict on whether Wolbachia-based control of vector-borne disease is more ‘evolution-402 
proof’ than drugs or insecticides awaits its long-term deployment in the field. However, there are 403 
grounds for optimism. Wolbachia is maintained at high frequency and retains its antiviral properties 404 
years after it is released into populations (11,14). RNA viruses, including DCV, frequently show 405 
considerable responses to selection in short-term laboratory experiments (33,53). Therefore our 406 
18 
 
results together with similar work in cell culture demonstrate that viruses do not readily evolve to 407 
escape Wolbachia’s effects (14). Nonetheless, in the wild viral population sizes are larger and 408 
selection will act for longer periods of time, so our results may not reflect the outcome of this 409 
interaction in nature. However, Wolbachia effectively protects against viruses that will have likely 410 
experienced many decades of selection because their natural hosts are Wolbachia-infected, 411 
suggesting that our experiments may reflect the outcome of evolution in nature (17,49,50) (although 412 
it is unclear whether the symbiont is an important selection pressure in natural populations of D. 413 
melanogaster (54,55)). Long-term monitoring of field populations will be essential to test whether 414 
this reflects fundamental biological constraints that prevent viruses evolving to escape from the 415 
effects of Wolbachia.  416 
 417 
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Figures and Tables 586 
 587 
Figure 1. Effect of Wolbachia on virus allele frequencies when selecting on a genetically diverse 588 
viral population. A genetically diverse population of DCV was passaged through Wolbachia-infected 589 
or Wolbachia-free flies and then sequenced. (A) Principal components analysis on allele frequencies 590 
of SNPs, where each point is an independent virus population (biological replicate). (B) Differences in 591 
the frequency of SNPs along the viral genome. The sequence reads were mapped to the DCV-C 592 
reference genome, and the heatmap shows the difference in the frequency of the allele carried by a 593 
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given DCV strain between Wolbachia treatments (frequency in Wolbachia-infected flies minus 594 
frequency in Wolbachia-free flies; red is a higher allele frequency in Wolbachia-infected flies). The 595 
tree was computed from the Euclidian distance computed from these differences in allele 596 
frequencies. (C) DCV phylogeny with bootstrap support for the nodes. (D) Differences in the 597 
frequency of isolate- or clade-specific variants between viral populations that had evolved in 598 
Wolbachia-infected and Wolbachia-free flies (positive numbers are more common in the presence of 599 
Wolbachia).  The number of SNPs is shown in parentheses, and the number in bold is the mean 600 
difference in frequency across all those SNPs. NA stands for cases where no isolate- or clade-specific 601 
SNPs could be found. 602 
 603 
 604 
Figure 2. Wolbachia’s effect on viral titers and virus-induced mortality in single virus infections. (A) 605 
Growth curves of three DCV isolates in Wolbachia-free and Wolbachia-infected flies. The lines are 606 
28 
 
asymptotic exponential curves and the shaded area 95% confidence intervals. (B) Survival curves 607 
following infection with DCV. (C) Wolbachia effect on virus-induced mortality expressed as –608 
ln(hazard ratio) where the hazard ratio is the probability of flies dying in Wolbachia-infected flies 609 
relative to their Wolbachia-free counterpart. Error bars are standard errors and *** P < 0.001. 610 
 611 
 612 
Figure 3. Presence of DCV and Wolbachia effect on viral titers in selection experiment 2. (A) Ct 613 
values obtained from qPCR reactions targeting DCV RNA in virus populations at different passages 614 
during selection. Populations passaged in Wolbachia-free flies were only checked for DCV infection 615 
at passage 10. Fractions at the top of the plot indicate the number of biological replicates for which 616 
DCV was detected relative to the total number of replicates (n = 25 in each selection treatment). (B) 617 
Virus titer of the DCV populations three-days post-infection in Wolbachia-free (black) and –infected 618 
(red) flies. Horizontal bold lines and dots indicate mean titers and values per biological replicate 619 
respectively. Error bars are standard errors. 620 
 621 
 622 
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 623 
 624 
Figure S1. Genetic differentiation of genetically diverse virus populations evolved in Wolbachia-625 
free and Wolbachia-infected Drosophila (selection experiment 1). (A) The vertical dashed line 626 
shows the observed mean genetic distance between DCV populations that had evolved in flies with 627 
different Wolbachia infection statuses. The bars show the null distribution of this statistic obtained 628 
by randomizing the Wolbachia treatments across the viral populations 1000 times. (B) Frequency of 629 
polymorphisms found in different DCV isolates or clades (see DCV phylogeny in Figure 1C). The 630 
number of SNPs is shown in parentheses, and the number in bold is the mean frequency across all 631 
the SNPs. NA stands for cases where no isolate-specific SNPs could be found. 632 
 633 
 634 
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 635 
Figure S2. Discriminant Analysis of Principal Components. (A) Distribution of virus populations 636 
along the discriminant function. (B) Contribution of DCV SNPs to the discriminant function. Numbers 637 
indicate SNP positions along the genome. The horizontal line is a threshold calculated using the 638 
Ward’s minimum variance clustering method. The positions of SNPs above this threshold which 639 
contribute most to the separation between Wolbachia treatments are indicated. (C) Relationship 640 
between changes in reference allele frequencies and the contribution of the respective SNPs to the 641 
discriminant function. The names of the DCV isolates or clades for a given allele are plotted. 642 
31 
 
 643 
Figure S3. Wolbachia effect on viral titers in selection experiment 1. Virus titer of the DCV 644 
populations three-days post-infection in Wolbachia-free (black) and –infected (red) flies. Horizontal 645 
bold lines and dots indicate mean titers and values per biological replicate respectively. Error bars 646 
are standard errors. *** indicate P < 0.001 in pairwise comparison tests between Wolbachia 647 
treatments. 648 
 649 
 650 
 651 
 652 
 653 
 654 
 655 
 656 
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Table S1. PCR and sequencing primers used to Sanger-sequence DCV genomes. 657 
Primer name Sequence 
DCV26F 5'-TGTACACACGGCTTTTAGGTAG-3' 
DCV874F 5'-TCTACCCTTAAGATGGTTGCTGA-3' 
DCV1046R 5'-TGACGTGCAGCTTCCTGTTT-3' 
DCV1478F 5'-AGTATCGTGCTTCTCTGTGTGT-3' 
DCV1774R 5'-CAGTGATCTTTTTAGCTCCCTCA-3' 
DCV2192F 5'-ATGTTCTTCGGGAAATGGGGA-3' 
DCV2350R 5'-GGTTAGCTGCTGTTTTGTCATC-3' 
DCV2875F 5'-GTCGATGATATTGCCAAACGC-3' 
DCV3044R 5'-TCGCTCAAACAAATGTCCATCC-3' 
DCV3920F 5'-ATTGTGTGCGCTTGCCATTT-3' 
DCV4022R 5'-AAATGCCGAACCAAATCACG-3' 
DCV4659F 5'-ATGTGGTGTAGACACTGCGG-3' 
DCV4857R 5'-TCCTGGTGACGTTGTACGAT-3' 
DCV5640F 5'-TGATGCAAAGGTTGTGGAATGG-3' 
DCV5732R 5'-CCAGTTTTAGCTTCGTCCGT-3' 
DCV6423F 5'-ACTACTCGTGAAGATCGTATCCA-3' 
DCV6666R 5'-GCATCAATCGTCCTTGCTGG-3' 
DCV7325F 5'-TGGTCAAGTTCGAATGGCGA-3' 
DCV7508R 5'-GGCATCGGTTGTGTTCCAAG-3' 
DCV8271F 5'-CCGGAAGCGCATTGTATTGG-3' 
DCV8444R 5'-AAGGGACATGGGTTCAGCAG-3' 
DCV9205R 5'-CGAAAAACCTGGTAGCCCCT-3' 
 658 
  659 
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Table S2. Depth of coverage per RNA library. There is no significant difference in coverage between 660 
Wolbachia treatments (t-test: t = -0.53 ; P = 0.6) 661 
Selection treatment Replicate population Mean depth of coverage 
No Wolbachia 1 72x 
No Wolbachia 2 76x 
No Wolbachia 3 71x 
No Wolbachia 4 84x 
No Wolbachia 5 87x 
No Wolbachia 6 83x 
No Wolbachia 7 84x 
No Wolbachia 8 74x 
No Wolbachia 9 75x 
No Wolbachia 10 71x 
No Wolbachia 11 70x 
No Wolbachia 12 68x 
Wolbachia 1 70x 
Wolbachia 2 71x 
Wolbachia 3 77x 
Wolbachia 4 84x 
Wolbachia 5 87x 
Wolbachia 6 89x 
Wolbachia 7 89x 
Wolbachia 8 70x 
Wolbachia 9 68x 
Wolbachia 10 75x 
Wolbachia 11 81x 
Wolbachia 12 79x 
 662 
  663 
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Table S3. Nucleotide composition of the sequenced genome of DCV isolates used in this study. 664 
DCV 
A C G T 
K   
(T/G) 
M  
(C/A) 
R  
(A/G) 
S    
(G/C) 
W 
(A/T) 
Y   
(C/T) 
Total 
isolates 
C 2712 1487 1856 3006 -  -  -  -  -  -  9061 
EB 2720 1481 1856 3003 -  -  -  -  -  1 9061 
CYG 2721 1484 1855 2998 -  -  -  -  -  3 9061 
G 2690 1425 1819 2949 4 4 50 1 8 110 9060 
M 2740 1469 1828 3022 -  -  -  -  -  -  9059 
Z 2741 1474 1826 3019 -  -  1 -  -  -  9061 
T 2740 1468 1829 3024 -  -  -  -  -  -  9061 
O 2706 1444 1818 3007 1 3 35 -  6 40 9060 
 665 
 666 
 667 
 668 
 669 
 670 
